General
Preferred name
VILOXAZINE
Synonyms
Viloxazine hydrochloride ()
SPN-812 ()
Viloxazine (hydrochloride) ()
viloxazine ER, Supernus Pharmaceuticals ()
Viloxazin (hydrochloride) ()
Emovit (hydrochloride) ()
Viloxazin ()
viloxazine ()
Viloxazine hcl ()
Vivalan ()
Qelbree ()
ICI 58,834 ()
ICI-58834 ()
P&D ID
PD009011
CAS
46817-91-8
35604-67-2
Tags
available
drug
Approved by
FDA
First approval
2021
Drug Status
investigational
approved
withdrawn
Drug indication
Attention deficit hyperactivity disorder
Antidepressant
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Viloxazine was originally described as a selective norepinephrine reuptake inhibitor (NRI), principally based on its ability to potentiate noradrenergic effects. It also modulates 5-HT (serotonin) activity, via antagonistic activity at 5-HT2B and agonistic activity at 5-HT2C receptors, and it increases extracellular 5-HT levels in the prefrontal cortex (PFC) . Viloxazine's chemical structure is different from conventional tri- or tetra-cyclic antidepressants. The INN stipulates a racemic mixture of enantiomers. We show the structure without specified stereochemistry to represent the mixture. The hydrocholride salt (SPN-812) was progressed by Supernus Pharmaceuticals for attention deficit hyperactivity disorder (ADHD) in children and adults.
(GtoPdb)
DESCPRITION
A morpholine derivative used as an antidepressant. It is similar in action to IMIPRAMINE.
PHARMACODYNAMICS
Viloxazine is a selective noradrenaline reuptake inhibitor (NRI) with minimal inhibitory effect on the reuptake of 5-HT. It is also shown to upregulate the levels of GABA-B receptors in the rat frontal cortex. It is shown to form a complex with the human norepinephrine transporter (hNET) [A19788].; The S(-)-stereoisomer of viloxazine exhibits more potent pharmacological actions [A19789].
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
1
Compound Sets
15
ChEMBL Approved Drugs
ChEMBL Drugs
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMatrix
Enamine BioReference Compounds
Guide to Pharmacology
Ki Database
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
Prestwick Chemical Library
ReFrame library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
43
Molecular Weight
237.14
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
5
Ring Count
2
Aromatic Ring Count
1
cLogP
1.45
TPSA
39.72
Fraction CSP3
0.54
Chiral centers
1.0
Largest ring
6.0
QED
0.84
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Source data
